Modality
Small Molecule
MOA
PARPi
Target
Nectin-4
Pathway
Sphingolipid
MigraineMDD
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ Oct 2029
Phase 1Current
NCT03728250
924 pts·MDD
2023-01→2029-10·Recruiting
NCT08835189
2,665 pts·Migraine
2018-05→2029-10·Completed
3,589 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-10-023.5y awayInterim· Migraine
2029-10-073.5y awayInterim· MDD
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Complet…
P1
Recruit…
Catalysts
Interim
2029-10-02 · 3.5y away
Migraine
Interim
2029-10-07 · 3.5y away
MDD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03728250 | Phase 1 | MDD | Recruiting | 924 | EDSS |
| NCT08835189 | Phase 1 | Migraine | Completed | 2665 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP |